These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 34990810)

  • 21. Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial.
    Gatechompol S; Kittanamongkolchai W; Ketloy C; Prompetchara E; Thitithanyanont A; Jongkaewwattana A; Buranapraditkun S; Alameh MG; Ubolyam S; Sophonphan J; Apornpong T; Kerr S; Kamarulzaman A; Siwamogsatham S; Kroon E; Puthanakit T; Patarakul K; Palaga T; Wijagkanalan W; Carpenter A; Hong L; Weissman D; Ruxrungtham K;
    Nat Microbiol; 2022 Dec; 7(12):1987-1995. PubMed ID: 36376393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
    Tian JH; Patel N; Haupt R; Zhou H; Weston S; Hammond H; Logue J; Portnoff AD; Norton J; Guebre-Xabier M; Zhou B; Jacobson K; Maciejewski S; Khatoon R; Wisniewska M; Moffitt W; Kluepfel-Stahl S; Ekechukwu B; Papin J; Boddapati S; Jason Wong C; Piedra PA; Frieman MB; Massare MJ; Fries L; Bengtsson KL; Stertman L; Ellingsworth L; Glenn G; Smith G
    Nat Commun; 2021 Jan; 12(1):372. PubMed ID: 33446655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice.
    Prompetchara E; Ketloy C; Alameh MG; Tharakhet K; Kaewpang P; Yostrerat N; Pitakpolrat P; Buranapraditkun S; Manopwisedjaroen S; Thitithanyanont A; Jongkaewwattana A; Hunsawong T; Im-Erbsin R; Reed M; Wijagkanalan W; Patarakul K; Techawiwattanaboon T; Palaga T; Lam K; Heyes J; Weissman D; Ruxrungtham K
    Nat Commun; 2023 Apr; 14(1):2309. PubMed ID: 37085495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The oral vaccine based on self-replicating RNA lipid nanoparticles can simultaneously neutralize both SARS-CoV-2 variants alpha and delta.
    Mohammadi G; Sotoudehnia Koranni Z; Jebali A
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108231. PubMed ID: 34655852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
    Liu H; Zhou C; An J; Song Y; Yu P; Li J; Gu C; Hu D; Jiang Y; Zhang L; Huang C; Zhang C; Yang Y; Zhu Q; Wang D; Liu Y; Miao C; Cao X; Ding L; Zhu Y; Zhu H; Bao L; Zhou L; Yan H; Fan J; Xu J; Hu Z; Xie Y; Liu J; Liu G
    Vaccine; 2021 Nov; 39(48):7001-7011. PubMed ID: 34750014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19.
    Kackos CM; Surman SL; Jones BG; Sealy RE; Jeevan T; Davitt CJH; Pustylnikov S; Darling TL; Boon ACM; Hurwitz JL; Samsa MM; Webby RJ
    Microbiol Spectr; 2023 Feb; 11(1):e0424022. PubMed ID: 36695597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants.
    Ye Z; Bonam SR; McKay LGA; Plante JA; Walker J; Zhao Y; Huang C; Chen J; Xu C; Li Y; Liu L; Harmon J; Gao S; Song D; Zhang Z; Plante KS; Griffiths A; Chen J; Hu H; Xu Q
    Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2311752120. PubMed ID: 38134199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2.
    Jawalagatti V; Kirthika P; Hewawaduge C; Yang MS; Park JY; Oh B; Lee JH
    Mol Ther; 2022 May; 30(5):1926-1940. PubMed ID: 35123065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains in mice.
    Zhang Q; Tiwari S; Wen J; Wang S; Wang L; Li W; Zhang L; Rawling S; Cheng Y; Jokerst J; Rana TM
    PLoS One; 2024; 19(4):e0300524. PubMed ID: 38635805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.
    Li M; Guo J; Lu S; Zhou R; Shi H; Shi X; Cheng L; Liang Q; Liu H; Wang P; Wang N; Wang Y; Fu L; Xing M; Wang R; Ju B; Liu L; Lau SY; Jia W; Tong X; Yuan L; Guo Y; Qi H; Zhang Q; Huang Z; Chen H; Zhang Z; Chen Z; Peng X; Zhou D; Zhang L
    Front Immunol; 2021; 12():697074. PubMed ID: 34262569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
    Sathe N; Shaikh S; Bhavsar M; Parte L; Gadiparthi A; Kad S; Sensarma S; Nalband H; Sangapillai R; Sivashanmuganathan S; Pusalkar R; Anandan S; Masand G; Pratapreddy K; Harinarayana Rao S; Gokhale A; Vidyadhar Reddy GEC; Karanam G; Phatarphekar A; Rao P; Ramana V; Ramnath RL
    Vaccine; 2024 Feb; 42(5):1051-1064. PubMed ID: 37816655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.
    Kingstad-Bakke B; Lee W; Chandrasekar SS; Gasper DJ; Salas-Quinchucua C; Cleven T; Sullivan JA; Talaat A; Osorio JE; Suresh M
    Proc Natl Acad Sci U S A; 2022 May; 119(20):e2118312119. PubMed ID: 35561224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.
    Fluckiger AC; Ontsouka B; Bozic J; Diress A; Ahmed T; Berthoud T; Tran A; Duque D; Liao M; McCluskie M; Diaz-Mitoma F; Anderson DE; Soare C
    Vaccine; 2021 Aug; 39(35):4988-5001. PubMed ID: 34304928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
    Seephetdee C; Bhukhai K; Buasri N; Leelukkanaveera P; Lerdwattanasombat P; Manopwisedjaroen S; Phueakphud N; Kuhaudomlarp S; Olmedillas E; Saphire EO; Thitithanyanont A; Hongeng S; Wongtrakoongate P
    Antiviral Res; 2022 Aug; 204():105370. PubMed ID: 35772601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SMART-lipid nanoparticles enabled mRNA vaccine elicits cross-reactive humoral responses against the omicron sub-variants.
    Mahalingam G; Rachamalla HK; Arjunan P; Karuppusamy KV; Periyasami Y; Mohan A; Subramaniyam K; M S; Rajendran V; Moorthy M; Varghese GM; Mohankumar KM; Thangavel S; Srivastava A; Marepally S
    Mol Ther; 2024 May; 32(5):1284-1297. PubMed ID: 38414245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of a SARS-CoV-2 spike protein ectodomain subunit vaccine with a squalene emulsion adjuvant in rodents and rhesus macaques.
    Solomadin M; Tabynov K; Petrovsky N; Tabynov K
    Hum Vaccin Immunother; 2023 Aug; 19(2):2258571. PubMed ID: 37880990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters.
    Frantz PN; Barinov A; Ruffié C; Combredet C; Najburg V; de Melo GD; Larrous F; Kergoat L; Teeravechyan S; Jongkaewwattana A; Billon-Denis E; Tournier JN; Prot M; Levillayer L; Conquet L; Montagutelli X; Tichit M; Hardy D; Fernandes P; Strick-Marchand H; Di Santo J; Simon-Lorière E; Bourhy H; Tangy F
    Nat Commun; 2021 Nov; 12(1):6277. PubMed ID: 34725327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine.
    Hawman DW; Meade-White K; Clancy C; Archer J; Hinkley T; Leventhal SS; Rao D; Stamper A; Lewis M; Rosenke R; Krieger K; Randall S; Khandhar AP; Hao L; Hsiang TY; Greninger AL; Gale M; Berglund P; Fuller DH; Rosenke K; Feldmann H; Erasmus JH
    EBioMedicine; 2022 Sep; 83():104196. PubMed ID: 35932641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonclinical safety assessment of an mRNA Covid-19 vaccine candidate following repeated administrations and biodistribution.
    Broudic K; Laurent S; Perkov V; Simon C; Garinot M; Truchot N; Latour J; Désert P
    J Appl Toxicol; 2024 Mar; 44(3):371-390. PubMed ID: 37723625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.